PL3419979T3 - Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe - Google Patents
Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidoweInfo
- Publication number
- PL3419979T3 PL3419979T3 PL17711330T PL17711330T PL3419979T3 PL 3419979 T3 PL3419979 T3 PL 3419979T3 PL 17711330 T PL17711330 T PL 17711330T PL 17711330 T PL17711330 T PL 17711330T PL 3419979 T3 PL3419979 T3 PL 3419979T3
- Authority
- PL
- Poland
- Prior art keywords
- oxazine
- pyrazolo
- dihydro
- carboxamide compounds
- carboxamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298657P | 2016-02-23 | 2016-02-23 | |
| PCT/IB2017/050844 WO2017145013A1 (en) | 2016-02-23 | 2017-02-15 | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
| EP17711330.5A EP3419979B1 (en) | 2016-02-23 | 2017-02-15 | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3419979T3 true PL3419979T3 (pl) | 2020-06-29 |
Family
ID=58347718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17711330T PL3419979T3 (pl) | 2016-02-23 | 2017-02-15 | Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10323042B2 (pl) |
| EP (1) | EP3419979B1 (pl) |
| JP (1) | JP6837072B2 (pl) |
| KR (1) | KR102148587B1 (pl) |
| CN (2) | CN113332292A (pl) |
| AU (1) | AU2017223132B2 (pl) |
| BR (1) | BR112018015191B1 (pl) |
| CA (1) | CA3015166C (pl) |
| DK (1) | DK3419979T3 (pl) |
| ES (1) | ES2775674T3 (pl) |
| HU (1) | HUE048658T2 (pl) |
| IL (1) | IL260536B (pl) |
| MX (1) | MX379704B (pl) |
| PL (1) | PL3419979T3 (pl) |
| PT (1) | PT3419979T (pl) |
| RU (1) | RU2719599C2 (pl) |
| SG (1) | SG11201806383TA (pl) |
| WO (1) | WO2017145013A1 (pl) |
| ZA (1) | ZA201804619B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2017000485A1 (en) * | 2015-06-17 | 2019-04-12 | Pfizer | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
| WO2020054657A1 (ja) | 2018-09-10 | 2020-03-19 | 科研製薬株式会社 | 新規ヘテロ芳香族アミド誘導体及びそれを含有する医薬 |
| CN113490739A (zh) * | 2019-01-23 | 2021-10-08 | 通路治疗公司 | 通过磷酸二酯酶4(pde4)抑制治疗癫痫的方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE239797T1 (de) | 1993-01-25 | 2003-05-15 | Takeda Chemical Industries Ltd | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| WO1998044955A1 (en) | 1997-04-09 | 1998-10-15 | Mindset Ltd. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| PT1206474E (pt) * | 1999-08-27 | 2004-10-29 | Abbott Lab | Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2 |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| WO2001062801A2 (en) | 2000-02-24 | 2001-08-30 | Washington University | Humanized antibodies that sequester amyloid beta peptide |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| AU3976402A (en) | 2000-11-03 | 2002-06-03 | Proteotech Inc | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| US20040132708A1 (en) | 2002-05-01 | 2004-07-08 | Wyeth | Process for preparing 6-alkylidene penem derivatives |
| AR039774A1 (es) | 2002-05-01 | 2005-03-02 | Wyeth Corp | 6-alquiliden-penems biciclicos como inhibidores de beta-lactamasas |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| CA2501945A1 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| WO2005025616A1 (ja) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | 抗体の用途 |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| US7632833B2 (en) * | 2004-07-01 | 2009-12-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| CA2575663C (en) | 2004-07-30 | 2013-04-23 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| NZ564187A (en) | 2005-05-12 | 2010-03-26 | Pfizer | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
| TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
| EP1899296B1 (en) | 2005-06-22 | 2010-11-17 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP1779848A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| WO2007102580A1 (ja) * | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | 多環式シンナミド誘導体 |
| JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | Ｈ３受容体のテトラリン拮抗薬 |
| HRP20110539T1 (hr) | 2006-04-21 | 2011-08-31 | Pfizer Products Inc. | PIRIDINO[3,4-b]PIRAZINONI |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| BRPI0806473A2 (pt) | 2007-01-22 | 2011-09-27 | Pfizer Prod Inc | sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo |
| KR101605576B1 (ko) * | 2008-05-27 | 2016-03-22 | 아스트라제네카 아베 | 페녹시피리디닐아미드 유도체 및 ｐｄｅ４ 매개 질환 상태의 치료에서의 그의 용도 |
| US20110039873A1 (en) * | 2009-06-08 | 2011-02-17 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| AR079967A1 (es) | 2010-01-26 | 2012-02-29 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos |
| MD20150071A2 (ro) * | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| CN107074845A (zh) * | 2014-07-30 | 2017-08-18 | 持田制药株式会社 | 吡唑衍生物的制造方法 |
| HUE044040T2 (hu) * | 2014-08-06 | 2019-09-30 | Pfizer | Imidazopiridazin vegyületek |
-
2017
- 2017-02-15 AU AU2017223132A patent/AU2017223132B2/en active Active
- 2017-02-15 ES ES17711330T patent/ES2775674T3/es active Active
- 2017-02-15 RU RU2018128781A patent/RU2719599C2/ru active
- 2017-02-15 DK DK17711330.5T patent/DK3419979T3/da active
- 2017-02-15 WO PCT/IB2017/050844 patent/WO2017145013A1/en not_active Ceased
- 2017-02-15 HU HUE17711330A patent/HUE048658T2/hu unknown
- 2017-02-15 JP JP2018544154A patent/JP6837072B2/ja active Active
- 2017-02-15 MX MX2018010177A patent/MX379704B/es unknown
- 2017-02-15 KR KR1020187023853A patent/KR102148587B1/ko active Active
- 2017-02-15 CN CN202110445183.8A patent/CN113332292A/zh active Pending
- 2017-02-15 EP EP17711330.5A patent/EP3419979B1/en active Active
- 2017-02-15 SG SG11201806383TA patent/SG11201806383TA/en unknown
- 2017-02-15 US US16/074,290 patent/US10323042B2/en active Active
- 2017-02-15 PL PL17711330T patent/PL3419979T3/pl unknown
- 2017-02-15 CA CA3015166A patent/CA3015166C/en active Active
- 2017-02-15 CN CN201780013020.4A patent/CN108699080B/zh active Active
- 2017-02-15 BR BR112018015191-2A patent/BR112018015191B1/pt active IP Right Grant
- 2017-02-15 PT PT177113305T patent/PT3419979T/pt unknown
-
2018
- 2018-07-11 IL IL260536A patent/IL260536B/en active IP Right Grant
- 2018-07-11 ZA ZA2018/04619A patent/ZA201804619B/en unknown
-
2019
- 2019-05-31 US US16/427,627 patent/US10738063B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3015166A1 (en) | 2018-08-31 |
| MX2018010177A (es) | 2019-01-21 |
| HUE048658T2 (hu) | 2020-07-28 |
| KR102148587B1 (ko) | 2020-08-26 |
| CA3015166C (en) | 2021-08-03 |
| KR20180101568A (ko) | 2018-09-12 |
| DK3419979T3 (da) | 2020-03-23 |
| US10738063B2 (en) | 2020-08-11 |
| JP2019505558A (ja) | 2019-02-28 |
| RU2018128781A (ru) | 2020-03-24 |
| CN108699080A (zh) | 2018-10-23 |
| ZA201804619B (en) | 2020-12-23 |
| AU2017223132B2 (en) | 2019-12-05 |
| US10323042B2 (en) | 2019-06-18 |
| WO2017145013A1 (en) | 2017-08-31 |
| PT3419979T (pt) | 2020-03-26 |
| IL260536B (en) | 2020-10-29 |
| ES2775674T3 (es) | 2020-07-27 |
| CN108699080B (zh) | 2021-05-14 |
| EP3419979B1 (en) | 2020-01-29 |
| AU2017223132A1 (en) | 2018-07-26 |
| RU2719599C2 (ru) | 2020-04-21 |
| RU2018128781A3 (pl) | 2020-03-24 |
| BR112018015191B1 (pt) | 2023-10-17 |
| JP6837072B2 (ja) | 2021-03-03 |
| US20190300546A1 (en) | 2019-10-03 |
| MX379704B (es) | 2025-03-11 |
| CN113332292A (zh) | 2021-09-03 |
| EP3419979A1 (en) | 2019-01-02 |
| BR112018015191A2 (pt) | 2018-12-18 |
| SG11201806383TA (en) | 2018-09-27 |
| US20190055262A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3177285A4 (en) | [5,6]-fused bicyclic antidiabetic compounds | |
| EP3177614A4 (en) | [7,6]-fused bicyclic antidiabetic compounds | |
| IL254167A0 (en) | Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline | |
| GB201614314D0 (en) | Antibiotic compounds | |
| IL257757A (en) | Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | |
| EP3573975A4 (en) | LINKS | |
| EP3573976A4 (en) | COMPOUNDS | |
| ZA201804619B (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| EP3573956A4 (en) | LINKS | |
| IL257413A (en) | Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials | |
| ZA201805158B (en) | Carbapenem compounds | |
| EP3573980A4 (en) | LINKS | |
| GB201602235D0 (en) | Antibacterial compounds | |
| ZA201606522B (en) | Novel 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds | |
| HK1262816A1 (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| HK40026512A (en) | Antibacterial compounds | |
| HK40030345A (en) | Morpholinylpyridone compounds | |
| HK40030346A (zh) | 吡啶基吡啶酮化合物 | |
| HK40030198A (en) | Senolytic compounds | |
| HK40026592A (en) | Antibacterial compounds | |
| HK40026217A (en) | Antibacterial compounds | |
| ZA201801639B (en) | Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials | |
| AU2017905122A0 (en) | Compounds | |
| HK40004225A (en) | New antibacterial compounds | |
| HK40010325A (en) | Antibiotic compounds |